COVID-19 and Cardiovascular Comorbidities
- PMID: 33157558
- DOI: 10.1055/a-1269-1405
COVID-19 and Cardiovascular Comorbidities
Abstract
The emergence of a new coronavirus - severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - has resulted in a global pandemic. The associated coronavirus disease 2019 (COVID-19) has resulted in a high number of death worldwide. Observational studies and case reports have provided insights that older age and the presence of chronic diseases is frequently associated with a higher COVID-19 severity. These individuals also seem to have a higher risk of mortality due to COVID-19. In this review we provide insights into the impact chronic diseases associated with the cardiovascular system, such as obesity, diabetes mellitus, hypertension and cardiovascular disease might have on SARS-CoV-2 infection and COVID-19. Additionally we review recommendations and guidance's of international scientific associations and discuss which key learnings might be of importance for the future.
Thieme. All rights reserved.
Conflict of interest statement
DMW receives honoraria for advisory boards and speaker bureaus from Amarin, Amgen, AstraZeneca, Boehringer Ingelheim GmbH, Daiichi-Sankyo, Lilly, Novo Nordisk, MSD, Novartis, and Sanofi. NM, MD and KF do not have any conflict of interest with regard to this publication. OS is founder and director of Sciarc GmbH (Baierbrunn, Germany) and received honoraria as an advisor from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Mundipharma, Novo Nordisk, Roche Diabetes Care and Sanofi.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
